Skip to content

Catalyst Pharmaceutical CPRX Finance Lease Liabilities

Finance Lease Liabilities at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$3M-80.7%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$58.37M-2.9%

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's finance lease liabilities?
Catalyst Pharmaceutical (CPRX) reported finance lease liabilities of $0 in Q1 2026.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.